Most Common Side Effects of Polivy and Their Frequencies
Polivy (polatuzumab vedotin-piiq), used with bendamustine and rituximab for relapsed or refractory diffuse large B-cell lymphoma, has side effects tracked in clinical trials like GO29365. The table below lists the main ones (incidence ≥20% in combination therapy arm) from the prescribing information.
| Side Effect | Frequency (All Grades) | Frequency (Grades 3-4) |
|------------------------------|------------------------|------------------------|
| Neutropenia | 42% | 39% |
| Thrombocytopenia | 34% | 26% |
| Anemia | 33% | 15% |
| Peripheral neuropathy | 40% | 4% |
| Fatigue | 30% | 6% |
| Diarrhea | 29% | 6% |
| Pyrexia | 24% | <1% |
| Decreased appetite | 22% | 2% |
| Pneumonia | 19% | 15%* |
*Note: Pneumonia listed as ≥20% in some summaries but 19% precisely; severe infections are a key risk.[1][2]
How Often Do Severe Side Effects Occur?
Grades 3-4 (severe/life-threatening) effects hit about 70-80% of patients overall. Neutropenia leads at 39%, often requiring dose delays. Peripheral neuropathy builds over cycles (median onset 1.8 months), affecting 40% but rarely severe.[1][3]
Why Do Blood-Related Side Effects Dominate?
Polivy's antibody-drug conjugate targets CD79b, delivering chemotherapy-like toxin to B-cells, amplifying myelosuppression from bendamustine-rituximab. Lab abnormalities (e.g., low neutrophils 77% any grade) exceed clinical events due to monitoring.[1]
What Happens with Peripheral Neuropathy Over Time?
Starts early, peaks by cycle 4. 5% discontinue Polivy due to it; resolves or improves in 80% of cases post-treatment. Manage with dose reductions.[1][2]
Infection Risks Patients Face
Febrile neutropenia: 18% (all grades), 16% severe. Prophylaxis with G-CSF and antimicrobials cuts rates. Pneumonia/opportunistic infections tie to neutropenia.[1]
Discontinuation and Dose Adjustment Rates
23% stop Polivy due to adverse events (vs. 14% on BR alone). Most common reasons: neuropathy (5%), pneumonia (3%).[1]
Comparison to Bendamustine-Rituximab Alone
Polivy-BR boosts severe cytopenias: neutropenia 39% vs. 3%, thrombocytopenia 26% vs. 11%. But median survival improves (12.4 vs. 12.0 months).[1][3]
Sources:
[1] Polivy Prescribing Information (Genentech, 2023) - fda.gov
[2] Polivy Clinical Data Summary - polivy.com
[3] GO29365 Trial Results - nejm.org